Client Portfolio

genOway Serves Clients in 28 Countries Worldwide

Among those are 265 academic institutions, 13 EU framework projects, 70 biopharmaceutical, and 14 of the Top 20 pharma companies.

 

 

 

EU 6th and 7th Framework projects

genOway is involved in EU 6th and 7th Framework for several projects as a SME partner:

  • Aggressotype: Aggression subtyping for improved insight and treatment innovation in psychiatric disorders
  • AtheroBCells: Targeting and exploiting B cell functions for treatment in cardiovascular diseases
  • AtheroRemo: Inflammation and Vascular Wall Remodeling in Atherosclerosis
  • EURO-DIA: Functional genomics of Pancreatic beta cells and of tissues involved in control of the endocrine pancreas for prevention and treatment of type 2 diabetes
  • EVI-GENORET: Functional Genomics of the Retina in Health and disease
  • MATRICS: Focuses on the subtyping of agression both within Disruptive Behaviour Disorders and of the broader cross-disorder trait of aggression
  • RiskyCAD: Developing novel diagnostic tools and treatments to enhance personalized medicine of high risk coronary artery disease (CAD) patients
  • TACTICS: Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes
  • AD-Innov: Identify new therapeutics to treat Alzheimer disease
  • EPI-Vector: Treating genetic diseases by introducing functional genes into the human organism
  • EUGeneHeart: Genomics of Cardiomyocyte Signaling to Treat and Prevent Heart Failure
  • IT-Diab: Identify new targets implicated in the progression from prediabetes to Type 2 diabetes
  • MYORES: the European Muscle Development Network